Development of inhibitors of vascular adhesion protein-1 (VAP-1) as novel antiphlogistic agents

开发血管粘附蛋白-1 (VAP-1) 抑制剂作为新型抗炎药

• 批准号: 329739129
• 负责人: Professor Dr. Matthias Lehr
• 金额: --
• 依托单位: Institut für Pharmazeutische und Medizinische Chemie
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2017
• 资助国家: 德国
• 起止时间: 2016-12-31 至 2019-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/329739129?language=en
• 关键词: Development; inhibitors; vascular; adhesion; protein

The objective of the project is the development of new potent inhibitors of vascular adhesion protein-1 (VAP-1). This enzyme plays an important role in the pathogenesis of inflammatory diseases by participating in the extravasation of immune active cells from the blood into the inflamed tissue. A special focus shall be set on the selectivity and on the drug like properties of the molecules, in particular on metabolic stability and water solubility. The new agents could serve as biochemical tools to explore inflammatory processes, and, in an ideal case, they could be innovative, therapeutically useful antiphlogistics.

该项目的目标是开发新的有效的血管粘附蛋白-1（VAP-1）抑制剂。这种酶通过参与免疫活性细胞从血液外渗到发炎组织中，在炎症性疾病的发病机制中起重要作用。应特别关注分子的选择性和药物样性质，特别是代谢稳定性和水溶性。这些新药物可以作为探索炎症过程的生化工具，在理想的情况下，它们可以是创新的，治疗上有用的消炎药。